Wolfsegger Martin J
Department of Biostatistics, Baxter AG, Wagramer Strasse 17-19 IZD Tower 22nd Floor, 1220 Vienna, Austria.
J Pharmacokinet Pharmacodyn. 2007 Feb;34(1):103-13. doi: 10.1007/s10928-006-9037-x. Epub 2006 Oct 12.
Nonclinical in vivo animal studies have to be completed before starting clinical studies of the pharmacokinetic behavior of a drug in human subjects. The classic complete data design, where each animal is sampled for analysis once per time point, is usually only applicable for large animals using the traditional two-stage approach. The first stage involves estimation of pharmacokinetic parameters for each animal separately and the second stage uses the individual parameter estimates for statistical inference. In the case of rats and mice, where blood sampling is restricted, the batch design or the serial sacrifice design may be applicable. In batch designs samples are taken more than once from each animal, but not at all time points. In serial sacrifice designs only one sample is taken from each animal. In this paper, three methods are presented to construct confidence intervals for the ratio of two AUCs assessed in a serial sacrifice design, which can be used to assess bioequivalence in this parameter. The presented methods are compared in a simulation study.
在开始对药物在人体受试者中的药代动力学行为进行临床研究之前,必须先完成非临床体内动物研究。经典的完整数据设计是每个动物在每个时间点仅采样一次用于分析,通常仅适用于采用传统两阶段方法的大型动物。第一阶段涉及分别估计每只动物的药代动力学参数,第二阶段使用个体参数估计进行统计推断。对于大鼠和小鼠,由于血液采样受限,批次设计或连续牺牲设计可能适用。在批次设计中,从每只动物采集样本不止一次,但并非在所有时间点。在连续牺牲设计中,每只动物仅采集一个样本。本文提出了三种方法来构建在连续牺牲设计中评估的两个AUC比值的置信区间,可用于评估该参数的生物等效性。在模拟研究中对所提出的方法进行了比较。